← Back to Clinical Trials
Recruiting Phase 4 NCT06569953

Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial

Trial Parameters

Condition Acute Pain
Sponsor The Second Affiliated Hospital of Chongqing Medical University
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 284
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-08-26
Completion 2025-08-31
Interventions
Liposomal bupivacaineBupivacaine Hydrochloride

Brief Summary

The goal of this clinical trial is to evaluate the efficacy and safety of liposomal Bupivacaine administered by paravertebral block for the treatment of acute and chronic pain after video-assisted thoracoscopic lobectomy.

Eligibility Criteria

Inclusion Criteria: * Participants who scheduled for elective video-assisted thoracoscopic lobectomy under general anesthesia. * Participants were 18 years or older. * 18 kg/m2≤BMI≤30 kg/m2 * Participants with American Society of Anesthesiology (ASA) physical status I-III. * Understand the significance, possible benefits, potential risks of the trial in detail.Understand the procedures and methods of this study.Willing to complete the trial in strict compliance with the clinical trial protocol.Sign the informed consent form voluntarily. Exclusion Criteria: * with severe cardiovascular and cerebrovascular diseases such as myocardial infarction,unstable angina pectoris,severe cardiac rhythm disorders (second- and third-degree heart block,etc.), New York Heart Association (NYHA) functional class III/IV,Ischemic stroke. * with psychiatric disorders (such as schizophrenia,depression,etc.) and cognitive impairment. * with sensory disorders such as hyperalgesia. * with other bodily pain. * al

Related Trials